Business description: Perrigo Company plc

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

Number of employees: 8,379

Sales by Activity: Perrigo Company plc

Fiscal Period: December20202021202220232024

Consumer Self-Care Americas (Csca)

2.69B 2.69B 2.93B 2.96B 2.69B

Consumer Self-Care International(Csci)

1.4B 1.45B 1.53B 1.69B 1.68B

Prescription Pharmaceuticals (rx)

975M - - - -
See all business segments

Geographical breakdown of sales: Perrigo Company plc

Fiscal Period: December20202021202220232024

United States (U.S.)

3.44B 2.57B 2.87B 2.92B 2.65B

Europe (Excl. Ireland)

1.32B 1.37B 1.44B 1.58B 1.56B

All Other Countries

272M 180M 107M 116M 120M

Ireland

29.8M 23.7M 29.3M 40.8M 39.6M
See all geographic segments

Executive Committee: Perrigo Company plc

Manager TitleAgeSince
Chief Executive Officer 56 2023-06-29
Director of Finance/CFO 50 2022-05-15
Investor Relations Contact - 2011-06-30
Human Resources Officer 56 2013-04-30
See PERRIGO COMPANY PLC governance

Composition of the Board of Directors: Perrigo Company plc

Director TitleAgeSince
Director/Board Member 74 2014-10-31
Director/Board Member 60 2016-11-06
Director/Board Member 68 2017-02-05
Director/Board Member 69 2017-02-05
Director/Board Member 62 2017-05-01
Chairman 56 -
Director/Board Member 62 2022-07-29
Director/Board Member 56 2023-06-29
Director/Board Member 55 2023-10-31
Director/Board Member 57 2025-01-14
Composition of the Board of Directors

Shareholders: Perrigo Company plc

NameEquities%Valuation
T. Rowe Price Associates, Inc. (IM)
10.43 %
14,232,241 10.43 % 380 M $
Vanguard Fiduciary Trust Co.
10.24 %
13,968,429 10.24 % 373 M $
BlackRock Advisors LLC
9.278 %
12,657,998 9.278 % 338 M $
T. Rowe Price International Ltd.
8.116 %
11,073,026 8.116 % 296 M $
DFA Australia Ltd.
5.043 %
6,879,491 5.043 % 184 M $
List of PERRIGO COMPANY PLC shareholders

Company details: Perrigo Company plc

Perrigo Co. Plc

The Sharp Building Hogan Place

2/74, Dublin

+353 1 709 4000

http://www.perrigo.com
address Perrigo Company plc(PRGO)

Group companies: Perrigo Company plc

NameCategory and Sector
Pharmaceuticals: Major
Medical Distributors
Pharmaceuticals: Major
Financial Conglomerates
Medical Distributors
See all subsidiaries

Other Pharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
-0.15%-0.33%+2.57%-35.29% 3.73B
+1.10%+1.01%-15.58%+137.77% 698B
-0.29%-0.10%+5.69%-12.86% 375B
-0.16%-0.47%+12.97%+23.90% 335B
-1.53%+0.35%-54.14%+9.26% 313B
+0.89%-0.04%+6.30%-20.36% 259B
-0.16%-0.89%+0.47%+17.53% 240B
+0.21%-0.27%-13.25%-7.10% 217B
+2.81%+1.69%-33.53%-11.16% 204B
-0.06%-0.08%-6.11%+19.71% 160B
Average +0.25%+0.41%-9.46%+12.14% 280.61B
Weighted average by Cap. +0.31%+0.40%-10.80%+35.78%
See all sector performances
Trading Rating
Investor Rating
ESG MSCI
BBB
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
27.14USD
Average target price
36.50USD
Spread / Average Target
+34.49%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PRGO Stock
  4. Company Perrigo Company plc